SCHEMBL1723129

SCHEMBL1723129

c1ccc(CNc2ccc(CN3CCN(c4ccccc4)CC3)cc2)cc1

nearest known ligand 0.85

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 3/20 0.85
GAA P10253 2/20 0.82
POLB P06746 1/20 0.73
DRD4 P21917 5/20 0.71
MAPT P10636 1/20 0.58
ALOX15 P16050 1/20 0.58
ALOX12 P18054 1/20 0.58
MAPK1 P28482 1/20 0.58
GFER P55789 1/20 0.58
HIF1A Q16665 1/20 0.55
EPAS1 Q99814 1/20 0.55
KDM1A O60341 1/20 0.54
DRD2 P14416 2/20 0.54
DRD3 P35462 2/20 0.54
SIGMAR1 Q99720 1/20 0.53
MAP4K4 O95819 1/20 0.52
NTRK1 P04629 1/20 0.52
FLT3 P36888 1/20 0.52
HTR7 P34969 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2462363 0.91 L3MBTL1 (1.00) L3MBTL1GAAPOLBDRD4MAPT
SCHEMBL6057381 0.84 L3MBTL1 (0.66) L3MBTL1GAAPOLBHIF1AEPAS1
SCHEMBL6031812 0.84 DRD4 (1.00) DRD4DRD2DRD3SIGMAR1HTR7
SCHEMBL9742932 0.82 L3MBTL1 (0.67) L3MBTL1GAAPOLBDRD4MAPT
SCHEMBL24641969 0.81 L3MBTL1 (0.68) L3MBTL1GAAPOLBDRD4MAPT
SCHEMBL16102439 0.80 CHKA (0.71) L3MBTL1GAAPOLBMAPTALOX15
SCHEMBL5987431 0.78 DRD4 (0.64) L3MBTL1GAAPOLBDRD4DRD2
SCHEMBL13973336 0.78 DRD4 (0.64) L3MBTL1GAAPOLBDRD4MAPT
SCHEMBL12861757 0.78 DRD4 (0.79) DRD4DRD2DRD3SIGMAR1HTR7
SCHEMBL4649494 0.78 DRD4 (0.87) L3MBTL1GAADRD4MAPTDRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2344456-B1 NOVEL POTASSIUM CHANNEL BLOCKER JAPAN TOBACCO INC (JP) 2018-07-25 EP claimed
EP-2344456-B1 NOVEL POTASSIUM CHANNEL BLOCKER JAPAN TOBACCO INC (JP) 2018-07-25 EP disclosed
US-8258138-B2 Potassium channel blockers XENTION LIMITED (GB) 2012-09-04 US disclosed
EP-2344456-A1 NOVEL POTASSIUM CHANNEL BLOCKER Xention Limited (GB) 2011-07-20 EP disclosed
US-20100087437-A1 Novel Potassium Channel Blockers XENTION LIMITED (GB) 2010-04-08 US disclosed
WO-2010023445-A1 NOVEL POTASSIUM CHANNEL BLOCKER XENTION LIMITED (GB) 2010-03-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087437-A1 Novel Potassium Channel Blockers KCNB1, KCNJ2, KCNJ11 L3MBTL1 1696/4885GAA 3857/4885POLB 4525/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.